**Question:** All of the following are poor prognostic markers of CA Breast except

A. Estrogen Receptor (ER)
B. Progesterone Receptor (PR)
C. Human Epidermal Growth Factor Receptor 2 (HER2)
D. Ki-67

**Core Concept:** Poor prognostic markers in breast cancer refer to factors that indicate a higher likelihood of the cancer to recur, progress, or be resistant to treatment. In breast cancer, these markers are often used alongside others to determine treatment strategies and predict outcomes.

**Why the Correct Answer is Right:** ER, PR, and HER2 are collectively known as "AIM" markers, as they are associated with hormone receptor status and HER2 overexpression. These markers are generally considered good prognostic factors, as they are associated with better outcomes in breast cancer management. On the other hand, Ki-67 is a marker of cell proliferation, indicating high rates of cell division and poor prognosis.

**Why Each Wrong Option is Incorrect:**

A. Estrogen Receptor (ER) and Progesterone Receptor (PR) are good prognostic markers as they indicate a better response to hormone therapy.

B. Human Epidermal Growth Factor Receptor 2 (HER2) is also a good prognostic marker as its overexpression or gene amplification indicates a better response to targeted therapy.

C. Ki-67 (cell proliferation marker) is a poor prognostic marker, indicating higher rates of cell division and a poorer prognosis.

**Why the Correct Answer is Right**:

Ki-67 is a marker indicating the cell proliferation rate, which is associated with poor prognosis and increased risk of cancer recurrence or progression. It is useful in determining treatment options and predicting the response to therapy.

**Clinical Pearl:** Assessing the expression of these markers in breast cancer helps in clinical decision-making, guiding treatment options and predicting outcomes for patients. Understanding the role of these markers and their clinical implications is essential for medical professionals dealing with breast cancer management.